Update on the epidemiology and management of Staphylococcus aureus, including methicillin-resistant Staphylococcus aureus, in patients with cystic fibrosis

Anne Stone, Lisa Saiman

Research output: Contribution to journalReview article

37 Citations (Scopus)

Abstract

PURPOSE OF REVIEW: Staphylococcus aureus is one of the first and most common pathogens to be isolated from the respiratory tract of patients with cystic fibrosis. The prevalence of respiratory tract colonization/infection with both methicillin-susceptible and methicillin-resistant S. aureus has increased over the past decade. The clinical significance of colonization/infection with these pathogens is variable, leading to numerous therapeutic strategies: primary prophylaxis, eradication, treatment of cystic fiboris pulmonary exacerbations, and treatment of methicillin-resistant S. aureus. RECENT FINDINGS: Studies have demonstrated increased prevalence of S. aureus in clinical laboratories that use selective media. Additionally, small colony variant S. aureus has been associated with persistent infection, co-infection with Pseudomonas aeruginosa, and frequent courses of antibiotics, but this phenotype may be difficult to identify in clinical laboratories. Increased prevalence of methicillin-resistant S. aureus has led to use of oral and inhaled antibiotics in attempts to eradicate this pathogen; these studies have yielded variable results. SUMMARY: The epidemiology of S. aureus in cystic fibrosis has changed. Studies are needed to assess the clinical significance of the increased prevalence of both methicillin-susceptible and methicillin-resistant S. aureus, and whether primary prophylaxis or new treatment/eradication protocols are effective.

Original languageEnglish (US)
Pages (from-to)515-521
Number of pages7
JournalCurrent opinion in pulmonary medicine
Volume13
Issue number6
DOIs
StatePublished - Nov 1 2007
Externally publishedYes

Fingerprint

Methicillin-Resistant Staphylococcus aureus
Cystic Fibrosis
Staphylococcus aureus
Epidemiology
Methicillin
Anti-Bacterial Agents
Clinical Protocols
Infection
Coinfection
Respiratory Tract Infections
Respiratory System
Pseudomonas aeruginosa
Therapeutics
Phenotype
Lung

Keywords

  • Epidemiology
  • Eradication
  • Methicillin-resistant
  • Small colony variant
  • Staphylococcus aureus
  • Virulence

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

@article{15358efd93314e0da088361a14b0b091,
title = "Update on the epidemiology and management of Staphylococcus aureus, including methicillin-resistant Staphylococcus aureus, in patients with cystic fibrosis",
abstract = "PURPOSE OF REVIEW: Staphylococcus aureus is one of the first and most common pathogens to be isolated from the respiratory tract of patients with cystic fibrosis. The prevalence of respiratory tract colonization/infection with both methicillin-susceptible and methicillin-resistant S. aureus has increased over the past decade. The clinical significance of colonization/infection with these pathogens is variable, leading to numerous therapeutic strategies: primary prophylaxis, eradication, treatment of cystic fiboris pulmonary exacerbations, and treatment of methicillin-resistant S. aureus. RECENT FINDINGS: Studies have demonstrated increased prevalence of S. aureus in clinical laboratories that use selective media. Additionally, small colony variant S. aureus has been associated with persistent infection, co-infection with Pseudomonas aeruginosa, and frequent courses of antibiotics, but this phenotype may be difficult to identify in clinical laboratories. Increased prevalence of methicillin-resistant S. aureus has led to use of oral and inhaled antibiotics in attempts to eradicate this pathogen; these studies have yielded variable results. SUMMARY: The epidemiology of S. aureus in cystic fibrosis has changed. Studies are needed to assess the clinical significance of the increased prevalence of both methicillin-susceptible and methicillin-resistant S. aureus, and whether primary prophylaxis or new treatment/eradication protocols are effective.",
keywords = "Epidemiology, Eradication, Methicillin-resistant, Small colony variant, Staphylococcus aureus, Virulence",
author = "Anne Stone and Lisa Saiman",
year = "2007",
month = "11",
day = "1",
doi = "10.1097/MCP.0b013e3282efbbac",
language = "English (US)",
volume = "13",
pages = "515--521",
journal = "Current Opinion in Pulmonary Medicine",
issn = "1070-5287",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Update on the epidemiology and management of Staphylococcus aureus, including methicillin-resistant Staphylococcus aureus, in patients with cystic fibrosis

AU - Stone, Anne

AU - Saiman, Lisa

PY - 2007/11/1

Y1 - 2007/11/1

N2 - PURPOSE OF REVIEW: Staphylococcus aureus is one of the first and most common pathogens to be isolated from the respiratory tract of patients with cystic fibrosis. The prevalence of respiratory tract colonization/infection with both methicillin-susceptible and methicillin-resistant S. aureus has increased over the past decade. The clinical significance of colonization/infection with these pathogens is variable, leading to numerous therapeutic strategies: primary prophylaxis, eradication, treatment of cystic fiboris pulmonary exacerbations, and treatment of methicillin-resistant S. aureus. RECENT FINDINGS: Studies have demonstrated increased prevalence of S. aureus in clinical laboratories that use selective media. Additionally, small colony variant S. aureus has been associated with persistent infection, co-infection with Pseudomonas aeruginosa, and frequent courses of antibiotics, but this phenotype may be difficult to identify in clinical laboratories. Increased prevalence of methicillin-resistant S. aureus has led to use of oral and inhaled antibiotics in attempts to eradicate this pathogen; these studies have yielded variable results. SUMMARY: The epidemiology of S. aureus in cystic fibrosis has changed. Studies are needed to assess the clinical significance of the increased prevalence of both methicillin-susceptible and methicillin-resistant S. aureus, and whether primary prophylaxis or new treatment/eradication protocols are effective.

AB - PURPOSE OF REVIEW: Staphylococcus aureus is one of the first and most common pathogens to be isolated from the respiratory tract of patients with cystic fibrosis. The prevalence of respiratory tract colonization/infection with both methicillin-susceptible and methicillin-resistant S. aureus has increased over the past decade. The clinical significance of colonization/infection with these pathogens is variable, leading to numerous therapeutic strategies: primary prophylaxis, eradication, treatment of cystic fiboris pulmonary exacerbations, and treatment of methicillin-resistant S. aureus. RECENT FINDINGS: Studies have demonstrated increased prevalence of S. aureus in clinical laboratories that use selective media. Additionally, small colony variant S. aureus has been associated with persistent infection, co-infection with Pseudomonas aeruginosa, and frequent courses of antibiotics, but this phenotype may be difficult to identify in clinical laboratories. Increased prevalence of methicillin-resistant S. aureus has led to use of oral and inhaled antibiotics in attempts to eradicate this pathogen; these studies have yielded variable results. SUMMARY: The epidemiology of S. aureus in cystic fibrosis has changed. Studies are needed to assess the clinical significance of the increased prevalence of both methicillin-susceptible and methicillin-resistant S. aureus, and whether primary prophylaxis or new treatment/eradication protocols are effective.

KW - Epidemiology

KW - Eradication

KW - Methicillin-resistant

KW - Small colony variant

KW - Staphylococcus aureus

KW - Virulence

UR - http://www.scopus.com/inward/record.url?scp=34848890028&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34848890028&partnerID=8YFLogxK

U2 - 10.1097/MCP.0b013e3282efbbac

DO - 10.1097/MCP.0b013e3282efbbac

M3 - Review article

C2 - 17901758

AN - SCOPUS:34848890028

VL - 13

SP - 515

EP - 521

JO - Current Opinion in Pulmonary Medicine

JF - Current Opinion in Pulmonary Medicine

SN - 1070-5287

IS - 6

ER -